# A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation

> **NCT06006793** · PHASE1 · UNKNOWN · sponsor: **Shouyao Holdings (Beijing) Co. LTD** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** SY-5933

## Key facts

- **NCT ID:** NCT06006793
- **Lead sponsor:** Shouyao Holdings (Beijing) Co. LTD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-10
- **Primary completion:** 2025-02-15
- **Final completion:** 2025-08-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06006793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06006793, "A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06006793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*